Fiasp
My Prescription
Payment
Select pharmacy
$75.52
Print or send this coupon to your phone
AlbertsonsPowered byAbout Fiasp
Drug Details
Insulin aspart, also known as Fiasp, is a fast-acting insulin used to manage high blood sugar levels in individuals with type 1 or type 2 diabetes. By incorporating a balanced diet and regular exercise, insulin aspart aids in reducing the risk of complications such as kidney damage, blindness, nerve issues, and cardiovascular events like heart attacks or strokes. This synthetic insulin mimics natural human insulin and works by facilitating the absorption of glucose into cells for energy use. Unlike regular insulin, insulin aspart begins to work quickly but for a shorter duration. It is typically paired with a medium- or long-acting insulin to maintain stable blood sugar levels. Fiasp is available in several forms, including vials, pens, and cartridges, and can be administered via injection under the skin or through an insulin pump. It is suitable for adults and children over the age of two. While effective, users may experience side effects such as upper respiratory infections or the common cold. Always consult a healthcare professional before beginning any new medication regimen.
Price history for Fiasp
1 Vial, 10ML of 100UNIT/ML
Average retail price for Fiasp
Average SaveHealth price for Fiasp
Our price history data is based on aggregated prescription data collected from participating pharmacies in America. Our prescription data updates daily to reflect the latest price changes. If you notice a missing data point, it means there wasn't sufficient data available to generate a monetary value for that date.
*Retail prices are based on pharmacy claims data, and may not be accurate when we don't have enough claims.
Fiasp dosage forms
| Dosage | Quantity | Price from | Per unit |
|---|---|---|---|
| 10ML of 100UNIT/ML | 1 Vial | $81.10 | $81.10 |
| 10ML of 100UNIT/ML | 2 Vials | $155.42 | $77.71 |
| 10ML of 100UNIT/ML | 3 Vials | $224.63 | $74.88 |
Fiasp FAQs
Insulin aspart and Fiasp both contain the same active ingredient, insulin aspart, which is a rapid-acting insulin used to control blood sugar levels in people with diabetes. The primary difference between the two is that Fiasp has additional ingredients, such as niacinamide (vitamin B3) and L-arginine, which help it to be absorbed more quickly into the bloodstream. This results in Fiasp having a faster onset of action compared to traditional insulin aspart, allowing for more flexibility in timing with meals.
As of the latest information available, Fiasp is not being removed from the Pharmaceutical Benefits Scheme (PBS). However, changes to drug listings on the PBS can occur due to various reasons such as cost-effectiveness assessments, negotiations between the government and pharmaceutical companies, or changes in clinical guidelines. For the most accurate and up-to-date information, it is recommended to consult official announcements from the PBS or speak with a healthcare professional.
Tresiba and Fiasp are both insulin products used to manage blood sugar levels in individuals with diabetes, but they have different characteristics and purposes.Tresiba is a long-acting insulin, also known as insulin degludec. It is designed to provide a steady level of insulin over a 24-hour period or longer, helping to maintain baseline blood sugar levels.Fiasp, on the other hand, is a rapid-acting insulin, specifically insulin aspart. It is formulated to act quickly, usually within minutes, to manage blood sugar spikes that occur around meal times.In summary, Tresiba is used for long-term blood sugar control, while Fiasp is used for quick adjustments around meals.
Yes, Fiasp is still listed on the Pharmaceutical Benefits Scheme (PBS) in Australia.
Weight gain is not commonly associated with the use of Fiasp (insulin aspart). However, individual responses to insulin therapy can vary, and some people may experience changes in weight. It is important for patients to monitor their weight and discuss any concerns with their healthcare provider to ensure optimal management of their diabetes and overall health.